Efficacy and Safety of Zanubrutinib in the Treatment of Autoimmune Cytopenia Secondary to Indolent B-Cell Lymphoma.
10.19746/j.cnki.issn.1009-2137.2025.04.013
- Author:
Xiao-Pei WANG
1
;
Wei-Wei ZHANG
1
;
Wei SUN
1
;
Jia-Feng CHENG
1
Author Information
1. Department of Hematology, The Affiliated Hospital of Anhui University of Science and Technology (Dongfang General Hospital), Huainan 232001, Anhui Province, China.
- Publication Type:Journal Article
- Keywords:
indolent B-cell lymphoma;
autoimmune cytopenia;
zanubrutinib;
molecular targeted therapy
- MeSH:
Humans;
Pyrazoles/therapeutic use*;
Lymphoma, B-Cell/complications*;
Pyrimidines/therapeutic use*;
Piperidines/therapeutic use*;
Female;
Male;
Anemia, Hemolytic, Autoimmune/etiology*;
Thrombocytopenia/etiology*;
Middle Aged;
Purpura, Thrombocytopenic, Idiopathic/etiology*;
Treatment Outcome;
Adult;
Aged;
Cytopenia
- From:
Journal of Experimental Hematology
2025;33(4):1023-1028
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the efficacy and safety of zanubrutinib in the treatment of autoimmune cytopenia (AIC) secondary to indolent B-cell lymphoma (iBCL).
METHODS:A total of 23 patients with iBCL complicated with AIC who were admitted to our hospital from December 2019 to September 2023 were selected as the research subjects. All patients were administered zanubrutinib 160 mg, twice daily, and continued oral administration. The objective response rate (ORR) of AIC, the therapeutic effect on lymphoma, and the incidence of adverse reactions were observed.
RESULTS:After a median follow-up of 20 (5 to 48) months, the median duration of response was 9 (interquartile range [IQR] 5-24)months. AICA efficacy assessment showed that there were 10 cases of complete remission (CR), 9 cases of partial remission (PR), and 4 cases of no response (NR), and the ORR was 82.6% (19/23) (95%CI : 61.2-95.0). Among them, for the 14 patients with autoimmune hemolytic anemia (AIHA), 7 achieved CR, 5 had PR, and 2 had NR. For the 4 patients with immune thrombocytopenia (ITP), 1 reached CR, 2 had PR, and 1 had NR. Regarding the 5 patients with Evans syndrome (ES), 2 achieved CR, 2 had PR, and 1 had NR. The assessment of lymphoma efficacy showed that there were 10 cases of CR , 7 cases of PR , 6 cases of stable disease (SD), and no progressive cases, with an ORR of 73.9% (17/23) (95%CI : 51.6-89.8). The main adverse reactions during the treatment were infection, hemorrhage, neutropenia, elevated lymphocyte count, rash, and anemia. Most of these adverse reactions were grade 1-2 and tolerable. No arrhythmia and hypertension occurred, and no deaths due to adverse reactions.
CONCLUSION:Zanubrutinib is effective and safe for AIC secondary to iBCL.
